INDIANAPOLIS, May 6, 2024
/PRNewswire/ -- The board of directors of Eli Lilly and
Company (NYSE: LLY) has declared a dividend for the second
quarter of 2024 of $1.30 per share on outstanding common
stock.
The dividend is payable on June 10, 2024, to
shareholders of record at the close of business on May 16,
2024.
About Lilly
Lilly is a medicine company turning science into healing
to make life better for people around the world. We've been
pioneering life-changing discoveries for nearly 150 years, and
today our medicines help more than 51 million people across the
globe. Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and
affordable. To learn more, visit
Lilly.com and
Lilly.com/news. F-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains
forward-looking statements (as that term is defined in the Private
Securities Litigation Reform Act of 1995) about expected dividend
payments and reflects Lilly's current beliefs and
expectations. However, there are significant risks and
uncertainties in pharmaceutical research and development, as well
as in business development activities and capital allocation
strategies related to the company's business and actual results may
differ materially due to various factors. For further
discussion of risks and uncertainties relevant to Lilly's business
that could cause actual results to differ from Lilly's
expectations, see Lilly's Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this
release.
Refer
to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-473-5712 (Media)
|
|
Joe Fletcher;
jfletcher@lilly.com; 317-296-2884 (Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-declares-second-quarter-2024-dividend-302136873.html
SOURCE Eli Lilly and Company